Details for Patent: 12,023,328
✉ Email this page to a colleague
Which drugs does patent 12,023,328 protect, and when does it expire?
Patent 12,023,328 protects QINLOCK and is included in one NDA.
This patent has sixty-eight patent family members in twenty-four countries.
Summary for Patent: 12,023,328
| Title: | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
| Abstract: | Provided herein are low impurity compositions comprising a compound represented by Formula (I):which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof. |
| Inventor(s): | Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan |
| Assignee: | Deciphera Pharmaceuticals LLC |
| Application Number: | US18/518,110 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,023,328 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; Dosage form; |
Recent additions to Drugs Protected by US Patent 12,023,328
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharms | QINLOCK | ripretinib | TABLET | 213973 | May 15, 2020 | RX | Yes | 12,023,328 | ⤷ Start Trial | U-3957 | TREATMENT OF GASTROINTESTINAL STROMAL TUMOR COMPRISING ADMINISTERING ONCE DAILY, ONE OR MORE TABLETS COMPRISING RIPRETINIB | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 12,023,328
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 12,023,328 | ⤷ Start Trial | TREATMENT OF GASTROINTESTINAL STROMAL TUMOR COMPRISING ADMINISTERING ONCE DAILY, ONE OR MORE TABLETS COMPRISING RIPRETINIB | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,023,328
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 122354 | ⤷ Start Trial | |||
| Argentina | 122355 | ⤷ Start Trial | |||
| Australia | 2020417282 | ⤷ Start Trial | |||
| Australia | 2020419197 | ⤷ Start Trial | |||
| Australia | 2023241368 | ⤷ Start Trial | |||
| Australia | 2023248048 | ⤷ Start Trial | |||
| Australia | 2024227597 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
